Explore the Role and Influence of Bex gliflozin (A Type of SGLT-2 Inhibitors) in Type 2 Diabetes
DOI:
https://doi.org/10.54097/mtkrp596Keywords:
Type 2 diabetes, SGLT-2 Inhibitors, Bex gliflozin.Abstract
There are many chronic metabolic diseases in the world, and diabetes is one of them. Blood sugar control and improvement of insulin resistance are the main means of clinical treatment of type 2 diabetes (T2D). A variety of hypoglycemic drugs are now used in the clinic, but due to the different physical conditions of patients, only 50% of the drugs that may play a certain curative effect. Traditional T2D drug treatment relies on the regulation of insulin and has a variety of side effects. Bex gliflozin, as a sodium-glucose co-transporter 2 inhibitor (SGLT2i), the tubules have a reabsorption effect on glucose in the original urine, and the mechanism of action of Bex gliflozin is to inhibit this function of the kidneys, which makes part of the glucose not reabsorbed by the renal tubules and excreted with urine, thereby achieving the purpose of hypoglycemia. As an approved SGLT2i, it has shown good hypoglycemic effect and safety in the treatment of diabetes, combined with others. In addition, Bex gliflozin has a certain protective effect on the heart and kidneys, and some studies have shown that it has no significant effect on blood pressure and weight. This article summarizes the therapeutic progress and mechanism of SGLT2i and Bex gliflozin in T2D, in order to expanse of the indications for Bex gliflozin.
Downloads
References
Ding J C. Effects of Daglipzin, an SGLT-2 inhibitor, on cognitive function and related factors in middle-aged and elderly patients with type 2 diabetes mellitus [D]. Anhui Medical University, 2023.
American Diabetes Association (2011). Diagnosis and classification of diabetes mellitus. Diabetes care, 34 Suppl 1(Suppl 1), S62 – S69.
Allegretti, A. S., Zhang, W., Zhou, W., Thurber, T. K., Rigby, S. P., Bowman-Stroud, C., Trescoli, C., Serusclat, P., Freeman, M. W., & Halvorsen, Y. C. (2019). Safety and Effectiveness of Bex gliflozin in Patients with Type 2 Diabetes Mellitus and Stage 3a/3b CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation, 74 (3), 328 – 337.
Wright E. M. (2013). Glucose transport families SLC5 and SLC50. Molecular aspects of medicine, 34 (2-3), 183 – 196.
Ding B.X. Sodium-glucose cotransporter 2 and its inhibitors and related diseases [J/OL]. Chin J Biochem Mol Biol: 1 - 16.
Pode-Shakked, B., Reish, O., Aktuglu-Zeybek, C., Kesselman, D., Dekel, B., Bujanover, Y., & Anikster, Y. (2014). Bitterness of glucose/galactose: novel mutations in the SLC5A1 gene. Journal of pediatric gastroenterology and nutrition, 58 (1), 57 – 60.
Wright, E. M., Loo, D. D., & Hirayama, B. A. (2011). Biology of human sodium glucose transporters. Physiological reviews, 91 (2), 733 – 794.
Scafoglio, C., Hirayama, B. A., Kepe, V., Liu, J., Ghezzi, C., Satyamurthy, N., Moatamed, N. A., Huang, J., Koepsell, H., Barrio, J. R., & Wright, E. M. (2015). Functional expression of sodium-glucose transporters in cancer. Proceedings of the National Academy of Sciences of the United States of America, 112 (30), E4111 – E4119.
Scafoglio, C. R., Villegas, B., Abdelhady, G., Bailey, S. T., Liu, J., Shirali, A. S., Wallace, W. D., Magyar, C. E., Grogan, T. R., Elashoff, D., Walser, T., Yanagawa, J., Aberle, D. R., Barrio, J. R., Dubinett, S. M., & Shackelford, D. B. (2018). Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Science translational medicine, 10 (467), eaat5933.
Wells, R. G., Mohandas, T. K., & Hediger, M. A. (1993). Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere. Genomics, 17 (3), 787 – 789.
Hatano, M., Udagawa, T., Kanamori, T., Sutani, A., Mori, T., Sohara, E., Uchida, S., Morio, T., & Nishioka, M. (2022). A novel SLC5A2 heterozygous variant in a family with familial renal glucosuria. Human genome variation, 9 (1), 42.
Yu, L., Wu, M., Hou, P., & Zhang, H. (2020). SLC5A2 mutations, including two novel mutations, responsible for renal glucosuria in Chinese families. BMC nephrology, 21 (1), 69.
Cowie, M. R., & Fisher, M. (2020). SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature reviews. Cardiology, 17 (12), 761 – 772.
Margonato, D., Galati, G., Mazzetti, S., Cannistraci, R., Perseghin, G., Margonato, A., & Mortara, A. (2021). Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. Heart failure reviews, 26 (2), 337 – 345.
TheracosBio LLC. BRENZAVVY (bexagliflozin) tablets, for oral use: US prescribing information; 2023. https:// www. fda. gov/. Accessed 26 Jan 2023.
Liu Chongyu, Guo Chun. Bex gliflozin, Brenzavvy [J/OL]. Chinese Journal of Medicinal Chemistry: 1.
Halvorsen, Y. C., Walford, G. A., Massaro, J., Aftring, R. P., & Freeman, M. W. (2019). A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of Bex gliflozin as a monotherapy for adults with type 2 diabetes. Diabetes, obesity & metabolism, 21 (11), 2496 – 2504.
Halvorsen, Y. D., Conery, A. L., Lock, J. P., Zhou, W., & Freeman, M. W. (2023). Bex gliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism, 25 (10), 2954 – 2962.
Liu F Q, et al. Network meta-analysis of the risk of urinary tract or genital infection caused by sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus [J]. Chinese Journal of Diabetes Mellitus, 2019, 14 (8): 799 - 808.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
